There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Halozyme (HALO – Research Report), NeoGenomics (NEO – Research Report) and Ardelyx (ARDX – Research Report) with bullish sentiments.
Halozyme (HALO)
In a report released today, Joseph Catanzaro from Piper Sandler reiterated a Buy rating on Halozyme, with a price target of $48.00. The company’s shares closed last Tuesday at $36.00.
According to TipRanks.com, Catanzaro is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Halozyme with a $49.50 average price target, representing a 38.7% upside. In a report issued on February 13, Benchmark Co. also maintained a Buy rating on the stock with a $50.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
NeoGenomics (NEO)
In a report released today, David Westenberg from Piper Sandler reiterated a Buy rating on NeoGenomics, with a price target of $18.00. The company’s shares closed last Tuesday at $14.70.
According to TipRanks.com, Westenberg is a 3-star analyst with an average return of
Currently, the analyst consensus on NeoGenomics is a Strong Buy with an average price target of $20.33, a 45.0% upside from current levels. In a report issued on February 14, Leerink Partners also maintained a Buy rating on the stock.
Ardelyx (ARDX)
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Ardelyx today and set a price target of $12.00. The company’s shares closed last Tuesday at $8.55.
According to TipRanks.com, Raymond is a 4-star analyst with an average return of
Ardelyx has an analyst consensus of Strong Buy, with a price target consensus of $12.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HALO:
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
- Halozyme announces Takeda received EC approval for HYQVIA
- Halozyme announces approval for Vydura in Japan
- Halozyme price target lowered to $48 from $61 at H.C. Wainwright
- Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE
